C12Y 302/01166
Heparanase
Official title: Heparanase (3.2.1.166)
C12Y302/01166 (Heparanase) appears on 52 US grants and 83 published applications in this corpus.
Search patents in C12Y- Granted patents
- 52
- Published applications
- 83
- Assignees
- 45
- Inventors
- 126
- Latest grant
- 21 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 4 | 1 |
| 2002 | 7 | 12 |
| 2003 | 3 | 11 |
| 2004 | 5 | 14 |
| 2005 | 3 | 6 |
| 2006 | 3 | 5 |
| 2007 | 1 | 3 |
| 2008 | 1 | 1 |
| 2009 | 0 | 3 |
| 2010 | 5 | 2 |
| 2011 | 2 | 1 |
| 2012 | 1 | 2 |
| 2013 | 0 | 0 |
| 2014 | 1 | 1 |
| 2015 | 0 | 1 |
| 2016 | 2 | 3 |
| 2017 | 0 | 4 |
| 2018 | 0 | 1 |
| 2019 | 3 | 3 |
| 2020 | 0 | 1 |
| 2021 | 2 | 2 |
| 2022 | 2 | 1 |
| 2023 | 1 | 2 |
| 2024 | 0 | 1 |
| 2025 | 1 | 1 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Heparanase-neutralizing A54 monoclonal antibody21 Apr 2026US 12,606,637 B2Hadasit Medical Research Services and Development Ltd.
- Heparanase-neutralizing A54 monoclonal antibody23 Dec 2025US 12,503,518 B2Hadasit Medical Research Services and Development Ltd.
- Screening method for laminin 511 production promoting agent, basal epidermal layer stabilizing agent, and/or epidermal stem cells reduction inhibiting or proliferation promoting agent31 Jan 2023US 11,564,959 B2Shiseido Company, Ltd.
- Methods and kits for assessing Heparanase procoagulant activity, compositions comprising Heparanase, and methods for the treatment of coagulation-related disorders20 Sep 2022US 11,448,657 B2Rambam Med-Tech Ltd.
- Tumor infiltrating cells engineered to express a pro-inflammatory polypeptide15 Mar 2022US 11,273,177 B2Berkeley Lights, Inc.
- Novel glycan compounds for age-related macular degeneration8 Oct 2026US 2026/0306530 A1The Regents of the University of California
- Heparanase-neutralizing a54 monoclonal antibody1 May 2025US 2025/0136719 A1Hadasit Medical Research Services and Development Ltd.
- Compositions and methods for treating eye infections and disease11 Jul 2024US 2024/0230669 A1University of Virginia Patent Foundation
- Heparanase-neutralizing a54 monoclonal antibody24 Aug 2023US 2023/0265213 A1Hadasit Medical Research Services and Development Ltd.
- Screening method for laminin 511 production promoting agent, basal epidermal layer stabilizing agent, and/or epidermal stem cells reduction inhibiting or proliferation promoting agent6 Jul 2023US 2023/0210928 A1Shiseido Company, Ltd.
Most cited
By later US patents
- Heparanase derived from human Sk-Hep-1 cell line55US 5,362,641 AHadassah Medical Organization Kiryat Hadassah · 1994
- Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe39US 6,190,875 B1Hadasit Medical Research and Development Ltd. · 2001
- Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells37US 5,968,822 A1999
- Use of glycosaminoglycans degrading enzymes for management of airway associated diseases37US 6,153,187 AInsight Strategy & Marketing Ltd. · 2000
- Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II31US 5,262,403 ABoard of Regents, The University of Texas System · 1993